FDA halts allogeneic blood cancer trials after patient defect – STAT

by



[ad_1]

  1. FDA halts allogeneic blood cancer trials after patient defectSTAT
  2. Allogene Therapeutics Reports FDA Continued Clinical Trials of AlloCAR T Based on Single Patient CaseGlobeNewswire
  3. Allogene drops 36% after clinical discontinuation of AlloCAR T trialsIn search of the alpha
  4. Allogene Therapeutics stock drops to 40% as FDA suspends cancer drug studyMarketWatch
  5. Shares of cell therapy company Allogene drop nearly 40% after hours as FDA halts clinical trials – San Francisco Business TimesSan Francisco Business Hours
  6. See full coverage on Google News

[ad_2]

Source link